Empower Clinics Proposes Spin Out As Growth Of Research and Clinical Trials Accelerates With Multiple Clinical Study Applications

AGORACOM Small Cap CEO Interviews

Empower Clinics Proposes Spin Out As Growth Of Research and Clinical Trials Accelerates With Multiple Clinical Study Applications From Pharmaceutical Companies.

In a recent press release, Empower Clinics Inc. (CSE: EPW) (OTC: EPWCF) announced its proposal for a division spin-out and a strategic move towards the healthcare artificial intelligence (AI) sector. After a thorough strategic review, the company intends to complete a direct spin-out of its wholly-owned subsidiary, "Subco," and simultaneously acquire a healthcare AI technology or service company.

In this exclusive interview, Steven McAuley, Chairman & CEO of Empower Clinics, expressed his enthusiasm about this strategic move. He highlighted that this spin-out and focus on healthcare AI as a separate entity would unlock significant shareholder value and provide clarity to investors regarding each company's direction.

Regarding the Target, McAuley discussed the potential impact of AI and machine learning in the healthcare sector, particularly in patient recruitment for clinical trials. Empower's expertise in research and clinical trials uniquely positions them to understand the significance of AI in drug development. By applying AI algorithms to patient rosters and data, the industry can significantly improve patient recruitment speed, accuracy, and overall success rates in new drug development.

Overall, this strategic move by Empower Clinics marks a promising step into the fast-growing healthcare AI sector and represents an exciting opportunity for shareholders and investors alike. As developments unfold, investors are encouraged to stay informed about the company's progress in this transformative endeavor.

Now sit back relax and listen this powerful interview with Steven McAuley, Chairman & CEO of Empower Clinics.